All trading involves risk. Contracts for Difference (CFDs) are complex instruments and may not be suitable for all investors. Please refer to Risk Disclosure and Risk Fact Sheet on Capital.com/en-sg.
Open platformOpen platform

Vor Bio Amends Agreement With RemeGen To Add RC298 To Exclusive License Outside Greater China

By Reuters News

Nov 12 (Reuters) - RemeGen Co., Ltd. 688331.SS:

  • VOR BIO EXPANDS STRATEGIC PARTNERSHIP WITH REMEGEN, ADDING NEXT GENERATION, LONG-ACTING RC298 TO BAFF/APRIL FRANCHISE

  • VOR BIO - AMENDS AGREEMENT WITH REMEGEN TO ADD RC298 TO EXCLUSIVE LICENSE OUTSIDE GREATER CHINA

  • VOR BIO- RC298 INITIAL REGULATORY FILING ANTICIPATED IN H1 2027 IN CHINA

  • VOR BIO - TO PROVIDE REMEGEN $56 MILLION UPFRONT INCLUDING $10 MILLION CASH AND 2.3 MILLION SHARE WARRANTS

  • VOR BIO - REMGEN ELIGIBLE FOR UP TO $300 MILLION IN DEVELOPMENT MILESTONE PAYMENTS INCLUDING $20 MILLION FOR INITIAL MILESTONES

  • VOR BIO - CASH RUNWAY REAFFIRMED INTO EARLY 2029

Further company coverage: 688331.SS

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.